on behalf of the High-STEACS Investigators ABSTRACT BACKGROUND Major disparities between women and men in the diagnosis, management, and outcomes of acute coronary syndrome are well recognized.
I mportant disparities exist in the diagnosis, management, and outcomes of acute coronary syndrome between women and men (1) (2) (3) . Women with suspected acute coronary syndrome are less likely to undergo evidence-based investigations and treatment, and outcomes following myocardial infarction are consistently poorer compared with men (1) .
The development of high-sensitivity cardiac troponin assays has resulted in the identification of important sex differences in the reference range of cardiac troponin, with the 99th centile in men being twice that in women (4) (5) (6) . We have previously demonstrated that the use of a high-sensitivity assay with sex-specific thresholds may double the diagnosis of myocardial infarction in women and identify women at risk for future cardiac events (7) . This raises the question as to whether the use of single diagnostic thresholds has contributed to inequalities in the diagnosis, management, and outcomes of women with acute coronary syndrome.
The recently published fourth universal definition of myocardial infarction recommends the use of sexspecific thresholds for the diagnosis of myocardial infarction (2) .
High-STEACS (High-Sensitivity
Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome) was the first randomized controlled trial to evaluate the introduction of a high-sensitivity cardiac troponin I (hs-cTnI) assay with sex-specific thresholds into clinical practice (8) .
The hs-cTnI assay reclassified 1 in 6 patients with myocardial injury, but this was not associated with a reduction in recurrent myocardial infarction or cardiovascular death at 1 year. In this pre-specified secondary analysis, we evaluated the impact of implementing sex-specific diagnostic thresholds on the use of investigation and treatments for coronary heart disease and on clinical outcomes in women and men separately.
METHODS
STUDY DESIGN. High-STEACS was a steppedwedge, cluster-randomized controlled trial that evaluated the implementation of an hs-cTnI assay in consecutive patients presenting with suspected acute coronary syndrome across 10 secondary and tertiary hospitals in Scotland (NCT01852123) (Online Table 1 ). The study design has been described in detail previously (8) , and the study was conducted with the approval of Sex-Specific Thresholds of hs-cTnI international guidelines in use during enrollment (9, 10) . Throughout the duration of the trial, all sites measured cardiac troponin using both the cTnI and hs-cTnI assays simultaneously. During the validation phase, only the results of the cTnI assay were reported to the attending clinician, while during the implementation phase, only the results of the hs-cTnI assay were reported.
The cTnI assay (ARCHITECT STAT troponin I assay; Abbott Laboratories, Abbott Park, Illinois) with a single diagnostic threshold for women and men was used to guide clinical decisions during the validation phase. The interassay coefficient of variation was <10% at 40 ng/l at 7 sites and 50 ng/l at 3 sites, and these concentrations were used as the diagnostic thresholds during the validation phase (11) . During the implementation phase, an hs-cTnI assay (ARCHITECT STAT high-sensitive troponin I assay; Abbott Laboratories) was used to guide clinical decisions, with a sex-specific 99th centile diagnostic threshold of 16 ng/l for women and 34 ng/l for men (7) . centile while blinded to the study phase to classify patients in accordance with the third universal definition of myocardial infarction (12) . Any disagreements were resolved by a third physician (Online Appendix).
OUTCOMES. We used regional and national registries to ensure complete follow-up of the trial population (7, 13, 14) . The primary outcome was a composite of type 1 or type 4b myocardial infarction following the initial presentation to hospital or cardiovascular death within 1 year. The primary outcome was independently adjudicated by 2 physicians blinded to study phase, and any disagreements were resolved by a third physician.
STATISTICAL ANALYSIS. All patients with peak hs-cTnI above the sex-specific 99th centile were classi- 
RESULTS
Consecutive patients (n ¼ 48,282) with suspected acute coronary syndrome were included in this trial, of whom 22,562 (47%) were women and 25,720 (53%)
were men (Online Figure 1 ). Table 2 ).
DIAGNOSIS OF MYOCARDIAL INFARCTION DURING
INDEX ADMISSION. The adjudication panel was able to achieve a consensus diagnosis in 9,115 of 10,360 patients (88%) with hs-cTnI concentrations above the sex-specific 99th centile ( Figure 1 ). The proportions of women and men with myocardial injury due to type 1 myocardial infarction were 52% (1,609 of 3,118) and 65% (2,904 of 4,445) in those identified by the cTnI assay and 32% (401 of 1,270) and 40% (114 of 282) in those reclassified by the hs-cTnI assay (Online Table 2 ). Overall, the use of an hs-cTnI assay and sex-specific thresholds increased the diagnosis of type 1 myocardial infarction in women by 25% (from 1,609 of 21,959 [7%] to 2,010 of 21,959 [9%]) and in (21) Values are mean AE SD, n (%), or median (interquartile range). *Presenting symptom was missing in 5,615 patients (12%). †Two medications from aspirin, clopidogrel, prasugrel, or ticagrelor. ‡Includes warfarin and direct oral anticoagulant agents. §Electrocardiographic and physiological data were available in 1,377 of reclassified patients (78%) and 6,470 of identified patients (75%). kDefined as 2 or more tests within 24 h of presentation. ¶The adjudication panel was able to achieve consensus diagnoses in 9,098 of 10,360 patients (88%) with hs-cTnI concentrations above the sex-specific 99th centile.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated glomerular filtration rate; GRACE ¼ Global Registry of Acute Coronary Events; hs-cTnI ¼ high sensitivity cardiac troponin I; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention. and increased the diagnosis of nonischemic myocardial injury in women by 67% (from 1,000 of 21,959
[5%] to 1,673 of 21,959 [8%]) and in men by 12% (from 1,014 of 25,078 [2%] to 1,137 of 25,078 [2%]).
MANAGEMENT OF WOMEN AND MEN DURING INDEX
ADMISSION. Women with myocardial injury presenting in the implementation phase were more likely than those presenting during the validation phase to undergo coronary angiography (18% vs. 26%) and coronary revascularization (10% vs. 15%) (p < 0.001 
Non-ischemic myocardial injury
Adjudicated diagnoses are presented for patients with troponin concentration above the contemporary cardiac troponin I assay threshold of 50 ng/l and those with troponin concentration above the sex-specific 99th centile threshold of 16 ng/l in women and 34 ng/l in men. *Where there was consensus among the adjudication panel that there was insufficient clinical information to make a definitive diagnosis, because of missing admission or discharge letters, we did not attempt to adjudicate the diagnosis (1,245 of 10,360 [12%]). As we had access to all other information, including medical history, clinical investigations, management, and outcomes, these patients were not excluded from our primary or secondary analyses.
Lee et al. for both) ( Table 2, Online Tables 3 and 4 ). Similarly, in men with myocardial injury, coronary angiography and revascularization increased from the validation to implementation phase (38% vs. 46% and 26% vs. 34%, respectively; p < 0.001 for both). However, across both phases, rates of coronary angiography and revascularization were lower in women compared with men (p < 0.001 for both). Likewise, prescriptions for preventive therapies increased following implementation in both women and men but across both phases remained lower in women ( Table 2 ). These differences in management between women and men were also observed in patients older and younger than the median age of 73 years (Online Figure 2 ). Across both phases, women with type 1 myocardial infarction were less likely than men to undergo coronary angiography (43% vs. 66% during the validation phase and 53% vs. 73% during the implementation phase; p < 0.001 for both) and coronary revascularization (26% vs. 48% and 35% vs. 57%, respectively; p < 0.001 for both) (Online Table 5 , Online Figure 3 ). They were also less likely than men to receive prescriptions for secondary prevention such as dual-antiplatelet therapy (48% vs. 61% during the validation phase and 54% vs. 67% during the implementation phase; p < 0.001 for both), statins (24% vs. 37% and 31% vs. 41%, respectively; p < 0.001 for both), and beta-blockers (26% vs. 42% and 33% vs. 42%, respectively; p < 0.001 for both).
On comparing rates of the primary outcome between participants receiving different treatments, we observed heterogeneity between women and men ( Figure 2) . Women who received angiotensin-converting enzyme or angiotensin receptor blockers, statins, and beta-blockers had a similar reduction in risk for subsequent myocardial infarction or death from cardiovascular death as men. However, the ef- Table 11 ). Primary and secondary outcomes in those women and men with DAPT ¼ dual-antiplatelet therapy; other abbreviations as in Table 1 . 13.0% [74 of 569]) (Online Table 16 ).
DISCUSSION
The implementation of sex-specific thresholds for Paired log-rank test results are p ¼ 0.01 for men with myocardial injury and p ¼ 0.06 for men without myocardial injury. (Right) Cumulative incidence time-to-event curves for the primary outcome of myocardial infarction or cardiovascular death at 1 year for women admitted during the validation phase (dashed line) and implementation phase (solid line). Patients are grouped according to whether myocardial injury was present (red) or absent (gray). Paired log-rank test results are p ¼ 0.40 for women with myocardial injury and p ¼ 0.08 for women without myocardial injury. Sex-Specific Thresholds of hs-cTnI infarction in women and men (15) . The impact of sex-specific thresholds on the diagnosis of myocardial infarction has been evaluated in a number of observational studies with divergent findings (7, (16) (17) (18) (19) (20) .
Most of these studies enrolled selected patients with acute coronary syndrome, of whom the majority were men. Furthermore, sex-specific thresholds were not used to guide clinical care or subsequent investigation for coronary artery disease. Here, we imple- Sex-specific thresholds identified 5-times more additional women than men with myocardial injury Despite this, women received fewer treatments for coronary artery disease than men And their outcomes were not improved. Sex-specific thresholds identified 5 times more additional women than men with myocardial injury. Despite this, women received fewer treatments for coronary artery disease than men, and their outcomes were not improved. CI ¼ confidence interval; MI ¼ myocardial infarction.
Lee et al. cardiovascular death at 1 year (8) . Here, we report the primary outcome stratified by sex. The vast majority of patients reclassified by the sex-specific thresholds were women, but we did not observe any improvement in their outcomes. There was also no difference in the primary outcome in men, but as very few men were reclassified, we were underpowered for this subgroup.
A number of observations could explain our findings. First and perhaps most important, women were less likely to receive treatment for acute coronary syndrome than men. This was a consistent finding across both phases of the trial and in those with adjudicated diagnoses of type 1 myocardial infarction. The majority of patients reclassified by the hs-cTnI assay were women, who were less likely to receive evidence-based treatments than those already identified by the cTnI assay. This suggests that clinicians may be less willing to investigate or initiate treatment in patients with modest elevations in cardiac troponin. Second, we observed lower treatment efficacy for acute coronary syndrome in women compared with men. Third, women were older than men at presentation and more likely to die of noncardiovascular causes. It is possible that the opportunity to modify risk in this group of patients is more limited. However, it is unlikely that the lower provision and efficacy of treatment in women could be attributed to their older age at presentation alone. In a post hoc analysis, we observed that women younger than the median age were less likely to receive treatment than men of the same age. Furthermore, the observed differences in treatment efficacy between women and men were restricted to these younger women. It is plausible that the discordance in treatment provision and efficacy was due to differences in the pathophysiology of acute coronary syndromes between women and men. In observational studies, women are more likely than men to have plaque erosions and coronary microembolization (21), spontaneous coronary artery dissections (22) , and coronary microvascular dysfunction (23) , and women are consistently underrepresented in clinical trials of cardiovascular therapies (24) (25) (26) . Women may also have been subjected to clinician bias in the use of diagnostic tests or provision of therapies (27) or have had a disproportionate burden of psychosocial risk factors, such as depression or a lack of social support, which can influence subsequent cardiovascular risk (28) .
Should international guidelines recommend the use of sex-specific thresholds for the diagnosis of myocardial infarction? Although we did not directly compare a uniform 99th centile threshold against the sex-specific threshold in this trial, our study does provide some helpful insights into the use of sexspecific thresholds. First, use of sex-specific thresholds identifies similar proportions of women and men presenting with suspected acute coronary syndrome with myocardial injury. Second, women and men reclassified by the high-sensitivity assay with sexspecific thresholds were at similar risk for subsequent myocardial infarction or cardiovascular death.
Therefore, use of a lower 99th centile in women appropriately identified a group of women who were at risk for cardiovascular events. Conversely, women and men with hs-cTnI concentrations below their respective sex-specific diagnostic thresholds had similar rates of cardiovascular events, suggesting that the use of a higher 99th centile for men did not inappropriately exclude myocardial injury in those who may have benefited from being identified and treated.
STUDY LIMITATIONS. First, it is possible that our adjudication panel may have underdiagnosed type 1 myocardial infarction in women, as the rates of coronary angiography were one-half those of men. We must acknowledge that some misclassification may have occurred.
Second, our estimates of treatment efficacy are subject to confounding by indication. Despite optimal adjustment, patients selected for treatment are likely to differ substantially from those who did not receive treatment, and we are unable to adjust for this residual confounding.
Third, the impact of adopting sex-specific thresholds will differ at hospitals that use lower uniform thresholds for cardiac troponin, as fewer women would be reclassified following implementation of hs-cTnI into practice.
Fourth, we have implemented sex-specific 99th centile thresholds using a high-sensitivity troponin I assay in our trial, but there are many other highsensitivity assays in clinical use worldwide. All high-sensitivity cardiac troponin assays have demonstrated differences in the normal reference range between women and men, suggesting that this approach should be recommended for all assays (6) .
However, the impact of implementing sex-specific diagnostic thresholds will differ for those assays for which the difference between women and men is modest.
Fifth, our study population consists of patients who received troponin testing for suspected acute coronary syndrome in Scotland. We acknowledge that troponin testing may be performed for other reasons and varies across different health care systems Sex-Specific Thresholds of hs-cTnI (29, 30) . The impact of implementing high-sensitivity cardiac troponin testing is likely to differ when used in a less selected patient population and when introduced at hospitals that have used either higher or lower cardiac troponin thresholds than used here.
Finally, we did not directly compare whether the use of sex-specific thresholds was superior to a uniform threshold using a hs-cTnI assay. This question is being evaluated in a prospective cluster randomized controlled trial (CODE-MI [Hs-cTn-Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women] trial; NCT03819894) that will include a health economic analysis to determine whether adopting sex-specific thresholds and identifying more women at risk is cost effective.
CONCLUSIONS
We report that use of a hs-cTnI assay with sexspecific thresholds identified 5 times as many additional women with myocardial injury than men, such that the proportion of women and men with myocardial injury is now equivalent. Despite this increase, women remain less likely than men to receive treatment for myocardial infarction, and the rates of subsequent myocardial infarction or cardiovascular death were not substantially reduced in either women or men following the implementation of high-sensitivity troponin testing into clinical 
